Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) has a beta value of 0.44 and has seen 1.15 million shares traded in the last trading session. The IRWD stock price is -274.7% off its 52-week high price of $15.70 and 9.55% above the 52-week low of $3.79. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.14 million shares traded. The 3-month trading volume is 1.85 million shares.
The consensus among analysts is that Ironwood Pharmaceuticals Inc (IRWD) is Buy stock at the moment, with a recommendation rating of 1.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.08.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) trade information
Over the past 30 days, the shares of Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) have changed -2.56%. Short interest in the company has seen 11.93 million shares shorted with days to cover at 7.52.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 65.08% from current levels. The projected low price target is $5.0 while the price target rests at a high of $18.0. In that case, then, we find that the current price level is -329.59% off the targeted high while a plunge would see the stock gain -19.33% from current levels.
Ironwood Pharmaceuticals Inc (IRWD) estimates and forecasts
Figures show that Ironwood Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -48.34% over the past 6 months, with this year growth rate of 103.83%, compared to 18.30% for the industry. Revenue growth from the last financial year stood is estimated to be -19.30%.
6 analysts offering their estimates for the company have set an average revenue estimate of 91.25M for the current quarter. 6 have an estimated revenue figure of 96.67M for the next ending quarter. Year-ago sales stood 113.74M and 117.55M respectively for this quarter and the next, and analysts expect sales will shrink by -19.80% for the current quarter and -19.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -28.37% over the past 5 years.
IRWD Dividends
Ironwood Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)’s Major holders
Insiders own 1.69% of the company shares, while shares held by institutions stand at 109.66% with a share float percentage of 111.55%. Investors are also buoyed by the number of investors in a company, with Ironwood Pharmaceuticals Inc having a total of 327.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 22.88 million shares worth more than $149.16 million. As of 2024-06-30, BLACKROCK INC. held 14.5067% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 21.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $140.59 million and represent 13.6737% of shares outstanding.
